Updating results

151 results

Sort: Relevance | Date

Preventing recurrence of Clostridium difficile infection: bezlotoxumab (ES13)

Summary of the evidence on bezlotoxumab for preventing the recurrence of Clostridium difficile (C difficile) infection

Evidence summary Published June 2017

Obese, overweight with risk factors: liraglutide (Saxenda) (ES14)

Summary of the evidence on liraglutide for managing obesity and overweight with risk factors in adults to inform local NHS planning and decision-making

Evidence summary Published June 2017

Early breast cancer (preventing recurrence and improving survival): adjuvant bisphosphonates (ES15)

Summary of the evidence on adjuvant bisphosphonates for preventing recurrence or improving survival in people with early breast cancer

Evidence summary Published July 2017

Minimal change disease and focal segmental glomerulosclerosis in adults: rituximab (ES1)

Summary of the evidence on rituximab for minimal change disease and focal segmental glomerulosclerosis to inform local NHS planning and decision-making

Evidence summary Published November 2016

Mitochondrial disorders in children: Co-enzyme Q10 (ES11)

Summary of the evidence on co-enzyme Q10 for mitochondrial disorders in children to inform local NHS planning and decision-making

Evidence summary Published March 2017

Hyperhidrosis: oxybutynin (ES10)

Summary of the evidence on oxybutynin for treating hyperhidrosis (excessive sweating) to inform local NHS planning and decision-making

Evidence summary Published March 2017

Chronic obstructive pulmonary disease: fluticasone furoate, umeclidinium and vilanterol (Trelegy) (ES18)

Summary of the evidence on fluticasone furoate, umeclidinium and vilanterol (Trelegy) for chronic obstructive pulmonary disease (COPD) to inform local NHS

Evidence summary Published June 2018

Non-cystic fibrosis bronchiectasis: inhaled tobramycin (ES12)

ES12 Non-cystic fibrosis bronchiectasis: inhaled tobramycin Key points

Evidence summary Published April 2017

Generalised anxiety disorder: quetiapine (ESUOM12)

Summary of the evidence on quetiapine monotherapy for treating generalised anxiety disorder (GAD) to inform local NHS planning and decision-making

Evidence summary Published May 2013

Non-cystic fibrosis bronchiectasis: colistimethate sodium (ESUOM25)

Summary of the evidence on colistimethate sodium (Colobreathe) for non-cystic fibrosis bronchiectasis to inform local NHS planning and decision-making

Evidence summary Published January 2014

Schizophrenia: omega-3 fatty acid medicines (ESUOM19)

Summary of the evidence on omega-3 fatty acid medicines for treating schizophrenia to inform local NHS planning and decision-making

Evidence summary Published September 2013

Postural hypotension in adults: fludrocortisone (ESUOM20)

Summary of the evidence on fludrocortisone for treating postural hypotension in adults to inform local NHS planning and decision-making

Evidence summary Published October 2013

Chronic obstructive pulmonary disease: glycopyrronium bromide (ESNM9)

Summary of the evidence on glycopyrronium bromide for treating chronic obstructive pulmonary disease (COPD) to inform local NHS planning and decision-making

Evidence summary Published January 2013

Gastroparesis in adults: oral erythromycin (ESUOM13)

Summary of the evidence on oral erythromycin for gastroparesis (delayed stomach emptying) in adults to inform local NHS planning and decision-making

Evidence summary Published June 2013

Hyperhidrosis: oral glycopyrronium bromide (ESUOM16)

Summary of the evidence on oral glycopyrronium bromide for treating hyperhidrosis (excessive sweating) to inform local NHS planning and decision-making

Evidence summary Published July 2013

Bile acid malabsorption: colesevelam (ESUOM22)

Summary of the evidence on colesevelam for treating bile acid malabsorption (BAM) to inform local NHS planning and decision-making

Evidence summary Published October 2013

Difficult-to-treat scabies: oral ivermectin (ESUOM29)

Summary of the evidence on oral ivermectin for treating difficult-to-treat scabies to inform local NHS planning and decision-making

Evidence summary Published March 2014

Interstitial cystitis: dimethyl sulfoxide bladder instillation (ESUOM26)

Summary of the evidence on dimethyl sulfoxide bladder instillation for treating interstitial cystitis to inform local NHS planning and decision-making

Evidence summary Published February 2014

Inflammatory lesions of papulopustular rosacea: ivermectin 10 mg/g cream (ESNM68)

Summary of the evidence on ivermectin 10 mg/g cream for treating papulopustular rosacea to inform local NHS planning and decision-making

Evidence summary Published January 2016

Type 1 diabetes mellitus in adults: high-strength insulin glargine 300 units/ml (Toujeo) (ESNM62)

Summary of the evidence on high-strength insulin glargine 300 units/ml (Toujeo) for type 1 diabetes mellitus to inform local NHS planning and decision-making

Evidence summary Published October 2015

Facial erythema of rosacea: brimonidine tartrate gel (ESNM43)

Summary of the evidence on brimonidine tartrate gel for treating facial erythema of rosacea to inform local NHS planning and decision-making

Evidence summary Published July 2014

Systemic juvenile idiopathic arthritis: canakinumab (ESNM36)

Summary of the evidence on canakinumab for treating systemic juvenile idiopathic arthritis (JIA) to inform local NHS planning and decision-making

Evidence summary Published March 2014

Type 2 diabetes: insulin degludec/liraglutide (Xultophy) (ESNM60)

Summary of the evidence on insulin degludec/liraglutide (Xultophy) for treating type 2 diabetes to inform local NHS planning and decision-making

Evidence summary Published July 2015

Type 2 diabetes: alogliptin (ESNM20)

Summary of the evidence on alogliptin (a dipeptidyl peptidase-4 [DPP-4] inhibitor) for type 2 diabetes to inform local NHS planning and decision-making

Evidence summary Published May 2013 Last updated October 2014

Attention deficit hyperactivity disorder in children and young people: lisdexamfetamine dimesylate (ESNM19)

Summary of the evidence on lisdexamfetamine dimesylate for attention defecit hyperactivity disorder (ADHD) in children and young people..

Evidence summary Published May 2013

Lower urinary tract symptoms secondary to benign prostatic hyperplasia: tadalafil (ESNM18)

Summary of the evidence on tadalafil for lower urinary tract symptoms secondary to benign prostate hyperplasia..

Evidence summary Published May 2013 Last updated October 2013

Actinic keratosis: ingenol mebutate gel (ESNM14)

Summary of the evidence on ingenol mebutate gel for actinic keratosis (solar keratosis) to inform local NHS planning and decision-making

Evidence summary Published March 2013

Acute diarrhoea in children: racecadotril as an adjunct to oral rehydration (ESNM12)

Summary of the evidence on racecadotril with oral rehydration for treating acute diarrhoea in children to inform local NHS planning and decision-making

Evidence summary Published March 2013

Type 1 diabetes: insulin degludec (ESNM24)

Summary of the evidence on insulin degludec for treating type 1 diabetes to inform local NHS planning and decision-making

Evidence summary Published September 2013

Migraine prophylaxis: flunarizine (ESUOM33)

Summary of the evidence on flunarizine for treating migraine prophylaxis to inform local NHS planning and decision-making

Evidence summary Published September 2014

Autoimmune haemolytic anaemia: rituximab (ESUOM39)

Summary of the evidence on rituximab for treating autoimmune haemolytic anaemia (AIHA) to inform local NHS planning and decision-making

Evidence summary Published February 2015

Hypersexuality: fluoxetine (ESUOM46)

Summary of the evidence on fluoxetine for treating hypersexuality to inform local NHS planning and decision-making

Evidence summary Published July 2015

Polycystic ovary syndrome: metformin in women not planning pregnancy (ESUOM6)

Summary of the evidence on metformin for polycystic ovary syndrome (PCOS) in women not planning pregnancy to inform local NHS planning and decision-making

Evidence summary Published February 2013

Acute diarrhoea in adults: racecadotril (ESNM11)

Summary of the evidence on racecadotril for treating acute diarrhoea in adults to inform local NHS planning and decision-making

Evidence summary Published March 2013

Combined oral contraception: nomegestrol/estradiol (Zoely) (ESNM28)

Summary of the evidence on nomegestrol/estradiol (Zoely) for use as combined oral contraception to inform local NHS planning and decision-making

Evidence summary Published December 2013

Asthma: beclometasone/formoterol (Fostair) for maintenance and reliever treatment (ESNM22)

Summary of the evidence on beclometasone/formoterol (Fostair) for treating asthma to inform local NHS planning and decision-making

Evidence summary Published June 2013

Irritable bowel syndrome with constipation in adults: linaclotide (ESNM16)

Summary of the evidence on linaclotide for irritable bowel syndrome (IBS) with constipation in adults to inform local NHS planning and decision-making

Evidence summary Published April 2013

Pulmonary sarcoidosis: infliximab (ES2)

Summary of the evidence on infliximab for treating pulmonary sarcoidosis to inform local NHS planning and decision-making

Evidence summary Published December 2016

Pre-exposure prophylaxis of HIV in adults at high risk: Truvada (emtricitabine/tenofovir disoproxil) (ESNM78)

Summary of the evidence on Truvada (emtricitabine/tenofovir disoproxil) for pre-exposure prophylaxis (PrEP) of HIV in adults at high risk

Evidence summary Published October 2016

Reversal of the anticoagulant effect of dabigatran: idarucizumab (ESNM73)

Summary of the evidence on idarucizumab for reversing the anticoagulant effect of dabigtatran to inform local NHS planning and decision-making

Evidence summary Published May 2016

Partial-onset seizures in epilepsy: perampanel as adjunctive treatment (ESNM7)

Summary of the evidence on perampanel for partial-onset seizures in epilepsy (in people aged 12 and over) to inform local NHS planning and decision-making

Evidence summary Published December 2012

Type 2 diabetes: lixisenatide (ESNM26)

Summary of the evidence on lixisenatide (glucagon-like peptide-1 [GLP-1] mimetic) for treating type 2 diabetes to inform local NHS planning and decision-making

Evidence summary Published September 2013

Induction of labour: misoprostol vaginal delivery system (ESNM38)

Summary of the evidence on the misoprostol vaginal delivery system for induction of labour to inform local NHS planning and decision-making

Evidence summary Published March 2014 Last updated November 2014

Asthma: fluticasone/formoterol (Flutiform) combination inhaler (ESNM3)

Summary of the evidence on fluticasone/formoterol (Flutiform) combination inhaler for treating asthma to inform local NHS planning and decision-making

Evidence summary Published October 2012

Partial-onset seizures in epilepsy: zonisamide as monotherapy (ESNM17)

Summary of the evidence on zonisamide as monotherapy for children and young people with epilepsy to inform local NHS planning and decision-making

Evidence summary Published April 2013

Early and metastatic HER2-positive breast cancer: subcutaneous trastuzumab (ESNM13)

Summary of the evidence on subcutaneous trastuzumab for HER2-positive breast cancer to inform local NHS planning and decision-making

Evidence summary Published March 2013

Attention deficit hyperactivity disorder in children and young people: clonidine (ESUOM8)

Summary of the evidences on clonidine for attention deficit hyperactivity disorder (ADHD) in children and young people..

Evidence summary Published April 2013

Asthma: fluticasone furoate/vilanterol (Relvar Ellipta) combination inhaler (ESNM34)

Summary of the evidence on the fluticasone furoate/vilanterol (Relvar Ellipta) combination inhaler for asthma to inform local NHS planning and decision-making

Evidence summary Published March 2014

Oestrogen deficiency symptoms in postmenopausal women: conjugated oestrogens and bazedoxifene acetate (ES3)

Summary of the evidence on conjugated oestrogens and bazedoxifene acetate for oestrogen deficiency symptoms to inform local NHS planning and decision-making

Evidence summary Published December 2016

Chronic obstructive pulmonary disease: fluticasone furoate plus vilanterol (ESNM21)

Summary of the evidence on fluticasone furoate plus vilanterol for treating chronic obstructive pulmonary disease (COPD)..

Evidence summary Published June 2013